aTyr Pharma Announces Promotion of Leslie Nangle, Ph.D., to Vice President of Research
May 11 2021 - 8:00AM
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged
in the discovery and development of innovative medicines based on
novel biological pathways, today announced the promotion of Leslie
Nangle, Ph.D., to Vice President, Research. Dr. Nangle will serve
as a member of the company’s executive leadership team, managing
research and scientific operations. Dr. Nangle has served in
scientific research roles at aTyr since joining the company in
2007, including most recently as Senior Director and Head of
Research.
“Dr. Nangle has been an integral part of our
team and we are delighted to have her lead aTyr’s research
efforts,” said Sanjay S. Shukla, M.D., M.S., President and Chief
Executive Officer of aTyr. “Dr. Nangle has dedicated her career to
tRNA synthetase biology and the pathways they regulate, having
studied under Dr. Paul Schimmel, aTyr’s Co-Founder. With her
long-standing knowledge and experience in research and discovery
related to this novel biology, including leading the company’s
development work in Neuropilin-2 receptor biology, she is uniquely
positioned to continue the exciting work that we have ongoing
related to aTy’s mission to translate novel biological pathways
into transformative medicines for patients.”
“I am thrilled to advance my scientific career
at aTyr by leading this incredibly talented research team,” said
Dr. Nangle. “I look forward to continuing the groundbreaking
discovery and translational work elucidating these novel pathways
that we have identified, each representing previously unexploited
therapeutic intervention points. Our approach aims to target these
extracellular signaling pathways related to tRNA synthetases with
the most effective drug modality, focusing on monoclonal antibodies
and targeted biologics. I believe aTyr’s biology platform
represents a unique opportunity to develop potential new innovative
therapeutics that can make a lasting impact in diseases with high
unmet medical need.”
Dr. Nangle has over 20 years of experience in
research dedicated to extracellular tRNA synthetases. Throughout
her tenure at aTyr, she has co-developed and implemented the
company’s discovery platform to generate an intellectual property
estate of over 300 potential therapeutically relevant proteins and
has overseen research leading to the discovery of a splice variant
of histidyl-tRNA synthetase that has been shown to modulate the
immune system, providing the basis of aTyr’s lead program,
ATYR1923. Prior to joining aTyr, Dr. Nangle received a Ph.D. in
Macromolecular Cellular Structure and Chemistry from The Scripps
Research Institute in La Jolla, CA, studying the emerging linkage
between mutations in tRNA synthetases and inherited neuropathies
under the mentorship of Dr. Paul Schimmel, who co-founded aTyr in
2005. Dr. Nangle received a bachelor of science in biology from the
University of California at Santa Barbara. She is co-author or
co-inventor of over 75 publications and issued or pending U.S.
patents.
About aTyr
aTyr is a biotherapeutics company engaged in the
discovery and development of innovative medicines based on novel
biological pathways. aTyr’s research and development efforts are
concentrated on a newly discovered area of biology, the
extracellular functionality and signaling pathways of tRNA
synthetases. aTyr has built a global intellectual property estate
directed to a potential pipeline of protein compositions derived
from 20 tRNA synthetase genes and their extracellular targets.
aTyr’s primary focus is ATYR1923, a clinical-stage product
candidate which binds to the Neuropilin-2 receptor and is designed
to down-regulate immune engagement in inflammatory lung diseases.
For more information, please visit http://www.atyrpharma.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are usually
identified by the use of words such as “anticipates,” “believes,”
“estimates,” “expects,” “intends,” “may,” “plans,” “projects,”
“seeks,” “should,” “will,” and variations of such words or similar
expressions. We intend these forward-looking statements to be
covered by such safe harbor provisions for forward-looking
statements and are making this statement for purposes of complying
with those safe harbor provisions. These forward-looking statements
include statements regarding potential therapeutic benefits and
applications of our tRNA synthetase biology platform and related
product candidates; timelines and plans with respect to certain
development activities; and certain development goals. These
forward-looking statements also reflect our current views about our
plans, intentions, expectations, strategies and prospects, which
are based on the information currently available to us and on
assumptions we have made. Although we believe that our plans,
intentions, expectations, strategies and prospects, as reflected in
or suggested by these forward-looking statements, are reasonable,
we can give no assurance that the plans, intentions, expectations
or strategies will be attained or achieved. All forward-looking
statements are based on estimates and assumptions by our management
that, although we believe to be reasonable, are inherently
uncertain. Furthermore, actual results may differ materially from
those described in these forward-looking statements and will be
affected by a variety of risks and factors that are beyond our
control including, without limitation, uncertainty regarding the
COVID-19 pandemic, risks associated with the discovery, development
and regulation of our product candidates, the risk that we or our
partners may cease or delay preclinical or clinical development
activities for any of our existing or future product candidates for
a variety of reasons (including difficulties or delays in patient
enrollment in planned clinical trials), the possibility that
existing collaborations could be terminated early, and the risk
that we may not be able to raise the additional funding required
for our business and product development plans, as well as those
risks set forth in our most recent Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q and in our other SEC filings. Except
as required by law, we assume no obligation to update publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact:Ashlee DunstonDirector, Investor
Relations and Corporate Communicationsadunston@atyrpharma.com
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Apr 2023 to Apr 2024